XML 20 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenues:      
Total revenues $ 7,020 $ 6,883 $ 2,357
Operating expenses:      
Research and development 163,550 118,011 82,258
General and administrative 38,548 30,914 27,195
Gain on fair value remeasurement of contingent consideration     (6,862)
Litigation settlement related loss   12,500 15,000
Total operating expenses 202,098 161,425 117,591
Operating loss (195,078) (154,542) (115,234)
Investment and other income, net 37,215 13,113 2,909
Net loss $ (157,863) $ (141,429) $ (112,325)
Basic net loss per common share (in dollars per share) $ (2.45) $ (2.92) $ (2.4)
Diluted net loss per common share (in dollars per share) $ (2.45) $ (2.92) $ (2.4)
Shares used in calculating basic net loss per share (in shares) 64,395 48,449 46,888
Shares used in calculating diluted net loss per share (in shares) 64,395 48,449 46,888
Comprehensive loss:      
Net loss $ (157,863) $ (141,429) $ (112,325)
Other comprehensive income (loss):      
Unrealized gain (loss) on marketable securities 6 2,048 (634)
Comprehensive loss (157,857) (139,381) (112,959)
Product development and licensing agreements      
Revenues:      
Total revenues 13 278 56
Contracts and grants      
Revenues:      
Total revenues $ 7,007 $ 6,605 $ 2,301